Otonomy, Inc. (OTIC): Price and Financial Metrics
GET POWR RATINGS... FREE!
OTIC POWR Grades
- Growth is the dimension where OTIC ranks best; there it ranks ahead of 72.12% of US stocks.
- The strongest trend for OTIC is in Momentum, which has been heading down over the past 31 weeks.
- OTIC's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).
OTIC Stock Summary
- With a price/sales ratio of 627.54, Otonomy Inc has a higher such ratio than 98.57% of stocks in our set.
- Revenue growth over the past 12 months for Otonomy Inc comes in at -64.26%, a number that bests merely 4.35% of the US stocks we're tracking.
- Otonomy Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -50.76%, greater than the shareholder yield of only 4.76% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Otonomy Inc, a group of peers worth examining would be CAPR, CLSN, VBIV, BCDA, and SRRA.
- Visit OTIC's SEC page to see the company's official filings. To visit the company's web site, go to www.otonomy.com.
OTIC Price Target
For more insight on analysts targets of OTIC, see our OTIC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.63 | Average Broker Recommendation | 1.4 (Strong Buy) |
OTIC Stock Price Chart Interactive Chart >
OTIC Price/Volume Stats
| Current price | $2.26 | 52-week high | $6.98 |
| Prev. close | $2.25 | 52-week low | $2.01 |
| Day low | $2.20 | Volume | 110,244 |
| Day high | $2.30 | Avg. volume | 801,336 |
| 50-day MA | $2.30 | Dividend yield | N/A |
| 200-day MA | $3.69 | Market Cap | 127.96M |
Otonomy, Inc. (OTIC) Company Bio
Otonomy Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. The company was founded in 2008 and is based in San Diego, California.
Latest OTIC News From Around the Web
Below are the latest news stories about Otonomy Inc that investors may wish to consider to help them evaluate OTIC as an investment opportunity.
Looking Into Otonomy''s Return On Capital EmployedDuring Q1, Otonomy ''s (NASDAQ: OTIC ) reported sales totaled $90.00 thousand. Despite a 15.13% in earnings, the company posted a loss of $11.84 million. Otonomy collected $53.00 thousand in revenue during Q4, but reported earnings showed a $10.29 million loss. What Is ROCE? Changes in earnings and sales indicate shifts in Otonomy''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful Full story available on Benzinga.com |
In the clinic for June 16, 2021Clinical updates, including trial initiations, enrollment status and data readouts and publications: Clearside, Fibrogen, Fusion, Ironwood, KBP, Lundbeck, Novadip, Oncotelic, Organicell, Otonomy, Paratek, Regeneron, Reviral, Salarius, Springworks, Trevena. |
Otonomy announces phase I/II study expansion for OTO-413 in speech-in-noise hearing difficultyNo summary available. |
Increases to CEO Compensation Might Be Put On Hold For Now at Otonomy, Inc. (NASDAQ:OTIC)The underwhelming share price performance of Otonomy, Inc. ( NASDAQ:OTIC ) in the past three years would have... |
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing LossOTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohortExpansion study will support endpoint selection and powering for Phase 2Top-line results expected in mid-2022 SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of an expansion study for the Pha |
OTIC Price Returns
| 1-mo | -1.74% |
| 3-mo | -14.72% |
| 6-mo | N/A |
| 1-year | -39.25% |
| 3-year | -43.50% |
| 5-year | -85.49% |
| YTD | -65.07% |
| 2020 | 68.93% |
| 2019 | 107.03% |
| 2018 | -66.67% |
| 2017 | -65.09% |
| 2016 | -42.70% |
Continue Researching OTIC
Want to do more research on Otonomy Inc's stock and its price? Try the links below:Otonomy Inc (OTIC) Stock Price | Nasdaq
Otonomy Inc (OTIC) Stock Quote, History and News - Yahoo Finance
Otonomy Inc (OTIC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...